Clinical trials in bipolar mania: Implications in study design and drug development

Archives of General Psychiatry

Volumn 65, Issue 3, 2008, Pages 252-253

  Tohen, Mauricio ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORAZEPAM; PROTEIN KINASE C INHIBITOR; TAMOXIFEN CITRATE;

ADULT; BIPOLAR MANIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONVALESCENCE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; HOSPITALIZATION; HUMAN; NOTE; POSITIVE AND NEGATIVE SYNDROME SCALE; RATING SCALE; SYMPTOMATOLOGY; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE;

BIPOLAR DISORDER; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TAMOXIFEN;

EID: 40349098605     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2007.44     Document Type: Note

References (12)

1. Yildiz A, Guleryuz S, Ankerst DP, Öngür D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008;65(3):255-263.
2. Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, Manji HK. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007;9(6):561-570.
3. Keck PE, Welge JA, McElroy SL, Arnold LM, Strakowski SM. Placebo effect in randomized, controlled studies of acute bipolar mania and depression. Biol Psychiatry. 2000;47(8):748-755.
4. Sysko R, Walsh BT. A systematic review of placebo response in studies of bipolar mania. J Clin Psychiatry. 2007;68(8):1213-1217.
5. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442-455.
6. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry. 1990;47(12):1106-1111.
7. Tohen M, Zarate CA Jr, Hennen J, Khalsa HMK, Strakowski SM, Gebre-Medhin P, Salvatore P, Baldessarini RJ. The McLean-Harvard first-episode mania study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160(12):2099-2107.
8. Manji HK, Lenox RH. Ziskind-Somerfeld Research Award: protein kinase C signaling in the brain. Molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry. 1999;46(10):1328-1351.
9. Einat H, Yuan P, Szabo ST, Dogra S, Manji HK. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology. 2007;55(3-4):123-131.
10. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry. 2000;57(1):95-97.
11. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem. 1994;63(6):2361-2364.
12. Coyle JT, Manji HK. Getting balance: drugs for bipolar disorder share target. Nat Med. 2002;8(6):557-558.